CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
淋巴瘤 CAR-T 细胞治疗前桥接放疗期间及之后的治疗动力学与局部反应
英文原题：Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.
查看英文原题
Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
非霍奇金淋巴瘤（NHL）患者接受CAR-T 治疗前的桥接放疗（BR）可实现持久减瘤，但最佳剂量尚未明确。我们评估了本中心33例接受BR的复发/难治性NHL患者（大B细胞淋巴瘤[LBCL] 25例，套细胞淋巴瘤[MCL] 8例）局部进展（LP）的相关因素。采用影像引导放疗（IGRT），将“快速桥接反应”（RBR）定义为5次照射内体积缩小10%。我们估算了以死亡为竞争风险的LP累积发生率。在接受IGRT的患者中，19例LBCL患者有5例、7例MCL患者有5例出现RBR。6例发生LP（均为LBCL，18个月累积发生率19%），这些患者均未出现RBR；代谢肿瘤体积>100 mL的肿瘤LP风险较高。LBCL患者中，发生LP肿瘤在放疗期间的体积变化中位数为0%，未发生LP者为−4%。组织学类型、影像组学特征及实时放疗反应或可指导个体化BR。
展开英文摘要原文
Bridging radiotherapy (BR) prior to CAR-T for non-Hodgkin lymphoma (NHL) can achieve durable cytoreduction, but optimal dosing remains undefined.
We evaluated correlates of local progression (LP) among 33 patients (25 large B-cell lymphoma [LBCL], 8 Mantle Cell Lymphoma [MCL]) with relapsed/refractory NHL who received BR at our institution. Using image-guided radiotherapy (IGRT), we defined 'rapid bridging response' (RBR) as 10% volume reduction within 5 fractions.
We estimated the cumulative incidence of LP with death as a competing risk. Five of 19 LBCL and 5/7 MCL patients with IGRT experienced RBR. LP occurred in 6 patients (all LBCL, 18-month cumulative incidence 19%), none of whom had RBR, and was increased for tumors with metabolic tumor volume > 100 mL. Among LBCL patients, median volume change during radiation for tumors with LP was 0% vs -4% for those without. Histology, radiomic features, and real-time radiotherapy response may guide a personalized approach to BR.
论文信息
- 作者
- Klebaner D、Park NJ、Marar M、Frank M、Hiniker SM、Hoppe RT、Schroers-Martin J、Advani RH
- 单位
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.United States
- 期刊
- Leukemia & lymphoma2026 Mar
- 原文标识
- PubMed 41452055 · DOI 10.1080/10428194.2025.2602880